Clinical Trials Directory

Trials / Terminated

TerminatedNCT00918658

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity

Status
Terminated
Phase
Study type
Observational
Enrollment
34 (actual)
Sponsor
Case Comprehensive Cancer Center · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer. PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

Detailed description

OBJECTIVES: * To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays. * To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry. OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing. Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Conditions

Interventions

TypeNameDescription
OTHERbiologic sample preservation procedureAll specimens will be collected using the Pathology Residual Tissue Procurement.
OTHERimmunologic techniqueInformation about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
OTHERlaboratory biomarker analysisBone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Timeline

Start date
2008-04-01
Primary completion
2011-03-01
Completion
2011-03-01
First posted
2009-06-11
Last updated
2015-10-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00918658. Inclusion in this directory is not an endorsement.